North America Non-Alcoholic Steatohepatitis (Nash) Biomarker Market Forecast 2021-2028
- Report Description Table of Contents
- FAQs
KEY FINDINGS
The North America non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.02%, over the forecast period of 2021 to 2028. The favorable reimbursements across the healthcare infrastructure, the anticipated launch of pipeline molecules, the early diagnosis of NASH, and the rising incidence of diabetes and obesity, is expected to fuel the region's market growth.
MARKET INSIGHTS
The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is evaluated by assessing Canada and the United States. Non-alcoholic steatohepatitis (NASH) is the more critical form of non-alcoholic fatty liver disease. The term steatohepatitis entails fatty liver with inflammation or progressing damage similar to alcoholic liver disease. However, it occurs in individuals who either drink alcohol in moderation, or do not drink alcohol. Moreover, obesity and diabetes are the significant risk factors for non-alcoholic fatty liver disease, with their incidence continually rising in developed nations, like Canada.
Conversely, according to the Canadian Liver Foundation, non-alcoholic fatty liver disease (NAFLD) was estimated to be a very common condition across North America. It was also evaluated that nearly 20% and 4% of Canada's population has non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, respectively. While a simple fatty liver is a benign condition, NASH is typically associated with ongoing liver damage. Moreover, the disease can also lead to liver cancer, cirrhosis of the liver, as well as the need for a liver transplant. As a result, these factors are accredited to the North America non-alcoholic steatohepatitis (NASH) biomarker market growth, during the forecast years.
COMPETITIVE INSIGHTS
Some of the leading companies operating in the market are, Pfizer Inc, Novartis AG, Bristol-Myers Squibb, Gilead Sciences, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
The North America non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.02%, over the forecast period of 2021 to 2028. The favorable reimbursements across the healthcare infrastructure, the anticipated launch of pipeline molecules, the early diagnosis of NASH, and the rising incidence of diabetes and obesity, is expected to fuel the region's market growth.
MARKET INSIGHTS
The North America non-alcoholic steatohepatitis (NASH) biomarker market growth is evaluated by assessing Canada and the United States. Non-alcoholic steatohepatitis (NASH) is the more critical form of non-alcoholic fatty liver disease. The term steatohepatitis entails fatty liver with inflammation or progressing damage similar to alcoholic liver disease. However, it occurs in individuals who either drink alcohol in moderation, or do not drink alcohol. Moreover, obesity and diabetes are the significant risk factors for non-alcoholic fatty liver disease, with their incidence continually rising in developed nations, like Canada.
Conversely, according to the Canadian Liver Foundation, non-alcoholic fatty liver disease (NAFLD) was estimated to be a very common condition across North America. It was also evaluated that nearly 20% and 4% of Canada's population has non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, respectively. While a simple fatty liver is a benign condition, NASH is typically associated with ongoing liver damage. Moreover, the disease can also lead to liver cancer, cirrhosis of the liver, as well as the need for a liver transplant. As a result, these factors are accredited to the North America non-alcoholic steatohepatitis (NASH) biomarker market growth, during the forecast years.
COMPETITIVE INSIGHTS
Some of the leading companies operating in the market are, Pfizer Inc, Novartis AG, Bristol-Myers Squibb, Gilead Sciences, etc.
Our report offerings include:
- Explore key findings of the overall market
- Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
- Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
- Market Segmentation cater to a thorough assessment of key segments with their market estimations
- Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
- Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
- Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
- Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
North America Non-Alcoholic Steatohepatitis (Nash) Biomarker Market Forecast 2021-2028
Published By :Inkwood Research
How to Purchase
Purchase reports from our site in few easy clicks. Please follow the description given below to complete your purchase process.
Step 1:
Select the report title of your interest, and Click on Buy Now button next to the Price option.
Step 2:
You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.
Step 3:
After SignUp/Login, you will arrive at our Payment Page on Paypal. You will see your Order Summary as well as an option to Choose a way to pay. Select a Payment option from Pay with a Paypal account OR Pay with a Debit or Credit Card. MarketReportOnline accepts Visa, MasterCard, American Express and Discover through Paypal. Fill up the required details in the option of your choice.
Step 4:
Once you follow the required process in Step 3 as mentioned above, you have successfully completed the purchase process.
Step 5:
Once you have successfully completed the purchase process, you will receive a confirmation email. The report will then be emailed to you directly by the publisher, as per our agreement with the publisher. For Orders that are placed after working hours, the delivery of the reports will be made on the next business day. For orders that are placed during weekends, the delivery of the reports will be made on the next 'working' business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us.